TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35503768

Group type: EXPERIMENTAL
Intervention: Cycling (altering first-line empiric therapy for Gram-negative bacteria every other 6-weeks)
Number of subjects: 1613

Group type: COMPARATOR
Intervention: Mixing (changing antibiotic type every empiric antibiotic course)
Number of subjects: 1613

Group type: COMPARATOR
Intervention: Mixing
Number of subjects: 1613

Group type: EXPERIMENTAL
Intervention: Cycling and Mixing
Number of subjects: 1613
Study: 33847597

Group type: EXPERIMENTAL
Intervention: Mobile phone intervention based on an HIV risk prediction tool
Number of subjects: 192

Group type: COMPARATOR
Intervention: Control group (QR code only for resources on HIV health education)
Number of subjects: 192
Study: 35716698

Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33154508

Group type: EXPERIMENTAL
Intervention: Carbon-Heated Tobacco Product (CHTP) 1.0 for 5 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cigarettes (control group)
Number of subjects: 0
Study: 36253903

Group type: EXPERIMENTAL
Intervention: Low-fat, vegan diet and cooked soybeans (½ cup [86 g] daily)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group making no dietary changes
Number of subjects: 84
Study: 32394874

Group type: EXPERIMENTAL
Intervention: Combination therapy with liposomal amphotericin B (7.5 mg/kg, single dose) and short-course miltefosine (2.5 mg/kg/day for 14 days)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Miltefosine monotherapy (2.5 mg/kg/day for 28 days)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Miltefosine monotherapy
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 144
Study: 35939920

Group type: EXPERIMENTAL
Intervention: V‐NeST plus treatment as‐usual (TAU)
Number of subjects: 30

Group type: COMPARATOR
Intervention: TAU alone
Number of subjects: 30
Study: 33914314

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (1.5 mg/kg) + 50 mg dexketoprofen in 10 mL saline, administered 30 min before the procedure.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group received 50 mg dexketoprofen in 10 mL saline, administered 30 min before the procedure.
Number of subjects: 60
Study: 32102723

Group type: EXPERIMENTAL
Intervention: Exercise intervention group (IG)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 61
Study: 35313167

Group type: EXPERIMENTAL
Intervention: Adjuvant pertuzumab (P) added to trastuzumab and chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (Pla) added to trastuzumab and chemotherapy
Number of subjects: 0
Study: 33606918

Group type: EXPERIMENTAL
Intervention: Acarbose 50 mg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Acarbose 100 mg
Number of subjects: 72

Group type: COMPARATOR
Intervention: Sucrose alone
Number of subjects: 72
Study: 32859662

Group type: EXPERIMENTAL
Intervention: Tailored multistep intervention (IA) incorporating electronic PRO assessment, case vignette, and expert-consented treatment recommendations
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control arm (CA)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Tailored multistep intervention (IA)
Number of subjects: 79
Study: 35329262

Group type: EXPERIMENTAL
Intervention: Kegel Exercise Pregnancy Training (KEPT) app
Number of subjects: 10
Study: 33961667

Group type: EXPERIMENTAL
Intervention: Optimune intervention group (n = 181) received care as usual (CAU) plus 12‐month access to Optimune immediately after randomization.
Number of subjects: 363

Group type: COMPARATOR
Intervention: Control group (n = 182) received CAU and Optimune after a delay of 3 months.
Number of subjects: 363
Study: 35551600

Group type: EXPERIMENTAL
Intervention: AD036 (atomoxetine 80 mg and oxybutynin 5 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Atomoxetine 80 mg alone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 35567309

Group type: EXPERIMENTAL
Intervention: Transdiagnostic emotion regulation (ER) skills training
Number of subjects: 101

Group type: COMPARATOR
Intervention: Waitlist control (WLC)
Number of subjects: 101
Study: 32335511

Group type: EXPERIMENTAL
Intervention: Speeding prevalence in Villahermosa
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Speeding prevalence in León
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Speeding prevalence in Cuernavaca
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Speeding prevalence in Guadalajara-Zapopan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall speeding prevalence
Number of subjects: 0
Study: 34238537

Group type: EXPERIMENTAL
Intervention: Universal 2-piece glass fiber-reinforced composite resin post (UNI)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Composite resin-custom glass fiber post (CTM)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Adapted glass fiber post with post space preparation of the same size
Number of subjects: 39
Study: 33004790

Group type: EXPERIMENTAL
Intervention: 30 g whey protein drink (120 kcal)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (2 kcal)
Number of subjects: 20
Study: 36346309

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 33474583

Group type: EXPERIMENTAL
Intervention: Being overweight at 2-10 years of age
Number of subjects: 2149

Group type: EXPERIMENTAL
Intervention: Annual growth measures
Number of subjects: 2149

Group type: EXPERIMENTAL
Intervention: Being overweight (including obese) at 10 years
Number of subjects: 2149
Study: 32346686

Group type: EXPERIMENTAL
Intervention: Calcitriol and calcium carbonate
Number of subjects: 120

Group type: COMPARATOR
Intervention: Calcium carbonate (control)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 5 mg ZOL with calcitriol and calcium carbonate
Number of subjects: 120

Group type: COMPARATOR
Intervention: 5 mg ZOL with calcium carbonate (control)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: High VitD experimental group
Number of subjects: 120

Group type: COMPARATOR
Intervention: Low VitD control group
Number of subjects: 120
Study: 34363831

Group type: EXPERIMENTAL
Intervention: Valacyclovir (2 g immediate dose followed by 500 mg, twice a day, for 3 days) + Amoxicillin (1 g immediate dose followed by 500 mg, 4 times a day, for 7 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Amoxicillin (1 g immediate dose followed by 500 mg, 4 times a day, for 7 days) + Placebo
Number of subjects: 20
Study: 36416302

Group type: EXPERIMENTAL
Intervention: Proposed model for assessing treatment effect heterogeneity over exposure time
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Permutation test for the variance component of the heterogeneous treatment effect parameters
Number of subjects: 0
Study: 35167358

Group type: EXPERIMENTAL
Intervention: Hatha-based yoga program delivered via telehealth
Number of subjects: 0
Study: 36039009

Group type: EXPERIMENTAL
Intervention: solution-focussed education and counselling
Number of subjects: 44

Group type: COMPARATOR
Intervention: control group
Number of subjects: 44
Study: 34531878

Group type: EXPERIMENTAL
Intervention: Janus kinase (JAK) inhibitors for acute and chronic graft‐versus‐host disease (GVHD) and cytokine release syndrome (CRS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Janus kinase (JAK) inhibitors
Number of subjects: 0
Study: 32101767

Group type: EXPERIMENTAL
Intervention: Cap and run procedure
Number of subjects: 15

Group type: COMPARATOR
Intervention: Usual transfer
Number of subjects: 15
Study: 34887529

Group type: EXPERIMENTAL
Intervention: 10 mg/10 mg OLZ/SAM for 21 days
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 10 mg olanzapine for 21 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo for 21 days
Number of subjects: 60
Study: 33685474

Group type: EXPERIMENTAL
Intervention: Melatonin soft gelatin capsule (5 mg twice a day for 7 days) along with standard treatment for COVID-19.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard treatment for COVID-19 based on the Iranian Ministry of Health and Medical Education’s protocol for 7 days.
Number of subjects: 60
Study: 34898011

Group type: EXPERIMENTAL
Intervention: Self-monitoring and feedback (SM+FB) with access to a customized smartphone application providing three daily feedback messages.
Number of subjects: 502

Group type: COMPARATOR
Intervention: Self-monitoring without feedback (SM).
Number of subjects: 502
Study: 33711941

Group type: EXPERIMENTAL
Intervention: Personalized Hypertension Management (PHMA) intervention package including support for self-monitoring, supervised machine communications, daily education or reminder messages, weekly blood pressure notification, and quarterly signed feedback.
Number of subjects: 3352
Study: 35768902

Group type: EXPERIMENTAL
Intervention: 81 mg non-enteric coated aspirin for 1 week (NYU cohort)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 81 mg non-enteric coated aspirin for 4 weeks (Duke cohort)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 325 mg non-enteric coated aspirin for 4 weeks (Duke cohort)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Comparison of 81 mg and 325 mg non-enteric coated aspirin (Duke cohort)
Number of subjects: 150
Study: 33589771

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 0
Study: 35482631

Group type: EXPERIMENTAL
Intervention: Counterfactual condition
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 73
Study: 33359367

Group type: EXPERIMENTAL
Intervention: tDCS
Number of subjects: 106

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 106
Study: 32075605

Group type: EXPERIMENTAL
Intervention: Watching television (TV)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Playing computer and video games
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Electronic media communication (EMC)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Watching TV
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Playing computer and EMC
Number of subjects: 480
Study: 35093561

Group type: EXPERIMENTAL
Intervention: Anodic stimulation
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Symmetric biphasic stimulation (cathode-first)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Symmetric biphasic stimulation (anode-first)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Biphasic pulse order (anode first)
Number of subjects: 9
Study: 34330334

Group type: EXPERIMENTAL
Intervention: BREATHE Ethiopia
Number of subjects: 45

Group type: COMPARATOR
Intervention: Treatment as Usual
Number of subjects: 45
Study: 32569112

Group type: EXPERIMENTAL
Intervention: Training intervention
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 75
Study: 36006973

Group type: EXPERIMENTAL
Intervention: Nutrition Information Panel (NIP) with Added Sugar
Number of subjects: 2582

Group type: EXPERIMENTAL
Intervention: Teaspoons of Sugar
Number of subjects: 2582

Group type: EXPERIMENTAL
Intervention: Warning
Number of subjects: 2582

Group type: EXPERIMENTAL
Intervention: Health Star Rating (HSR) using Total Sugar
Number of subjects: 2582

Group type: EXPERIMENTAL
Intervention: HSR with Added Sugar
Number of subjects: 2582

Group type: EXPERIMENTAL
Intervention: Sugar in the Ingredients List
Number of subjects: 2582

Group type: COMPARATOR
Intervention: Control
Number of subjects: 2582
Study: 32000067

Group type: EXPERIMENTAL
Intervention: FFR-guided complete revascularization
Number of subjects: 1170

Group type: COMPARATOR
Intervention: Angio-guided complete revascularization
Number of subjects: 1170
Study: 35906990

Group type: EXPERIMENTAL
Intervention: Extended pre-quit varenicline treatment
Number of subjects: 320

Group type: COMPARATOR
Intervention: Standard pre-quit varenicline treatment
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Both positive and negative TOEs scores
Number of subjects: 320
Study: 34817599

Group type: EXPERIMENTAL
Intervention: Multimodal mental practice (MMMP) regimen
Number of subjects: 18

Group type: COMPARATOR
Intervention: Repetitive task practice (RTP) only regimen
Number of subjects: 18
Study: 32840621

Group type: EXPERIMENTAL
Intervention: Mindfulness-based self-care (MBSC) training
Number of subjects: 82

Group type: COMPARATOR
Intervention: Life-as-usual control
Number of subjects: 82
Study: 36111174

Group type: EXPERIMENTAL
Intervention: Electronically-delivered EMPOWER (EMPOWER-ED) protocol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment-as-usual (control)
Number of subjects: 0
Study: 33407580

Group type: EXPERIMENTAL
Intervention: Passive device (Wrex by Jaeco)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Semi-active device (Armon Ayura)
Number of subjects: 36
Study: 32770314

Group type: EXPERIMENTAL
Intervention: Total leukocytes count
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neutrophil count
Number of subjects: 0
Study: 34649978

Group type: EXPERIMENTAL
Intervention: Sivopixant 150 mg
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 34976108

Group type: EXPERIMENTAL
Intervention: AI + personalized sports management service
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 150
Study: 34119469

Group type: EXPERIMENTAL
Intervention: Therapy withdrawal
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control (continued therapy)
Number of subjects: 51
Study: 32037861

Group type: EXPERIMENTAL
Intervention: Aerobic training (stationary bicycle training, 4 weeks, 5 times per week, 30-minute sessions, intensity 65%-80% of maximal heart rate)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 20
Study: 35623995

Group type: EXPERIMENTAL
Intervention: Spotify patient-preferred music selection (Group I, n=37)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Minimalist hypnotic music with guided relaxation breathing (MHMGRB) (Group II, n=40)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Comparison between Group I and Group II
Number of subjects: 77
Study: 33876885

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided percutaneous neuromodulation (PNM) intervention on the sciatic nerve
Number of subjects: 30
Study: 32679434

Group type: EXPERIMENTAL
Intervention: Low Glycemic Load (GL) diet
Number of subjects: 23

Group type: COMPARATOR
Intervention: High Glycemic Load (GL) diet
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Low GL diet during rice meal challenge
Number of subjects: 23

Group type: COMPARATOR
Intervention: High GL diet during rice meal challenge
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: CGM measurements
Number of subjects: 23
Study: 35427446

Group type: EXPERIMENTAL
Intervention: Non-lexical training (N = 24)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Lexical training (N = 24)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Training in noise (N = 12)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Training in silence (N = 12)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Untrained control group (N = 14)
Number of subjects: 62
Study: 34769831

Group type: EXPERIMENTAL
Intervention: HIIT‐R
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: HIFT
Number of subjects: 20
Study: 32751430

Group type: EXPERIMENTAL
Intervention: Standardized instructions (EG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intuitive or non-standardized instructions (CG)
Number of subjects: 0
Study: 33165214

Group type: EXPERIMENTAL
Intervention: Prenatal repair
Number of subjects: 183

Group type: COMPARATOR
Intervention: Postnatal repair
Number of subjects: 183
Study: 34919239

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT) combined with plyometric exercise
Number of subjects: 32
Study: 32723722

Group type: EXPERIMENTAL
Intervention: Virtual reality mindful exposure therapy (VR-MET) sessions, daily surveys, and online peer-to-peer support for 21 days.
Number of subjects: 120
Study: 33870752

Group type: EXPERIMENTAL
Intervention: Behavioral strategies for PA
Number of subjects: 436
Study: 34291584

Group type: EXPERIMENTAL
Intervention: Insulin degludec/aspart (IDegAsp)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Basal insulin (control)
Number of subjects: 87
Study: 34460294

Group type: EXPERIMENTAL
Intervention: GSLC curriculum (Evolution: DNA and the Unity of Life)
Number of subjects: 2269

Group type: COMPARATOR
Intervention: Typical NGSS-friendly units without molecular genetics
Number of subjects: 2269
Study: 34120134

Group type: EXPERIMENTAL
Intervention: Observer Tool (OT+)
Number of subjects: 89

Group type: COMPARATOR
Intervention: No Observer Tool (OT-)
Number of subjects: 89
Study: 34034279

Group type: EXPERIMENTAL
Intervention: Hemocoagulase Bothrops Atrox
Number of subjects: 120

Group type: COMPARATOR
Intervention: Epinephrine
Number of subjects: 120
Study: 34818588

Group type: EXPERIMENTAL
Intervention: Smoking cessation intervention (motivational interviewing sessions, 2 weeks of nicotine replacement therapy)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Control group (standard care, referral to Quitline)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Intervention and Control
Number of subjects: 252
Study: 33719579

Group type: EXPERIMENTAL
Intervention: Naproxen (500 mg twice daily for 7 days)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo (7 days of treatment)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Physical rehabilitation program (12 weeks)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 69
Study: 32682994

Group type: EXPERIMENTAL
Intervention: Low sugar and carbohydrate education (LSC) + blinded CGM
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Low sugar and carbohydrate education (LSC) + TLE (16‐h fast/8‐h feed for 5 days per week) + blinded CGM
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Low sugar and carbohydrate education (LSC) + TLE + real time feedback via CGM
Number of subjects: 60
Study: 35609059

Group type: EXPERIMENTAL
Intervention: Case-male participants with highest dichotomy of Lipoprotein(a)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Control-male participants with highest dichotomy of Lipoprotein(a)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Case-female participants with highest dichotomy of C-Peptide
Number of subjects: 253

Group type: COMPARATOR
Intervention: Control-male participants with highest dichotomies of Atherogenic Index of Plasma and Castelli Risk Index I
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Case participants with highest quartile of C-Peptide
Number of subjects: 253

Group type: COMPARATOR
Intervention: Control participants with higher atherogenic indices of plasma and anthropometric values
Number of subjects: 253
Study: 33235447

Group type: EXPERIMENTAL
Intervention: Aerosol-inhaled amikacin
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Oral probiotics
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Combined vaccination
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 144
Study: 33242071

Group type: COMPARATOR
Intervention: Standard physiotherapy rehabilitation
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Walking with a weighted vest (WALK)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Combined NMES/Walk
Number of subjects: 67
Study: 35305906

Group type: COMPARATOR
Intervention: Paclitaxel-Coated Balloon (PCB) (SeQuent Please, B. Braun Melsungen; 3 μg/mm2)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Sirolimus-Coated Balloon (SCB) (SeQuent SCB, B. Braun Melsungen; 4 μg/mm2)
Number of subjects: 70
Study: 33026766

Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide topical solution, 45% (HP45)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 157
Study: 34606174

Group type: EXPERIMENTAL
Intervention: VEC (vincristine, etoposide, and carboplatin)
Number of subjects: 164

Group type: COMPARATOR
Intervention: CyVEC (cyclophosphamide, vincristine, etoposide, and carboplatin)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: ICRB A/B/C
Number of subjects: 164

Group type: COMPARATOR
Intervention: ICRB D/E
Number of subjects: 164
Study: 33422764

Group type: EXPERIMENTAL
Intervention: Rehabilitative exercise
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Baseline sVAP‐1 concentrations
Number of subjects: 60
Study: 32617691

Group type: EXPERIMENTAL
Intervention: Face-to-face training
Number of subjects: 384

Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 384
Study: 34379740

Group type: EXPERIMENTAL
Intervention: Remdesivir (RDV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline oxygen requirement
Number of subjects: 0
Study: 34348982

Group type: EXPERIMENTAL
Intervention: Palliative care interventions (specific interventions not detailed)
Number of subjects: 23
Study: 34528074

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 28
Study: 34529025

Group type: EXPERIMENTAL
Intervention: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) followed by Lenalidomide maintenance therapy
Number of subjects: 54
Study: 33874968

Group type: EXPERIMENTAL
Intervention: Yarrow liver compresses applied externally once daily during radiation therapy (RT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Palliative radiation therapy (RT) alone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Yarrow liver compresses
Number of subjects: 24
Study: 35820664

Group type: EXPERIMENTAL
Intervention: Oral fluid HIV self-test
Number of subjects: 170

Group type: COMPARATOR
Intervention: Blood-based HIV self-test
Number of subjects: 170
Study: 33775203

Group type: EXPERIMENTAL
Intervention: Periodized training group (PG), n = 25
Number of subjects: 50

Group type: COMPARATOR
Intervention: Non-periodized training group (NPG), n = 25
Number of subjects: 50
Study: 32706343

Group type: EXPERIMENTAL
Intervention: Autologous platelet concentrates (APC), specifically platelet rich fibrin (PRF) and platelet rich plasma (PRP)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Autologous platelet concentrates (APC)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 7
Study: 35595645

Group type: EXPERIMENTAL
Intervention: 12-weeks of low-load blood-flow restricted (BFR) resistance training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (non-exercising)
Number of subjects: 20
Study: 32712606

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 48